AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00972478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00972478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT05504057 — intervention group
Intervention type: DRUG
Intervention: Antihistamine
Description: Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of survival among patients previously treated with
Study NCT05504057 — intervention group
Intervention type: DRUG
Intervention: Amantadine
Description: Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of survival among patients previously treated with amantadine
Study NCT02235623 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single-stage Fowler-Stephens orchidopexy (FSO)
Study NCT02235623 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Two-stage Fowler-Stephens orchidopexy (FSO)
Study NCT02942355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Anastrozole by mouth daily
Study NCT02942355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib by mouth daily days 1-21 every 28 days
Study NCT03659734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Guided Opioid Tapering Support
Description: Following surgery, participants will undergo motivational interviewing with a trained member of the study staff. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
Study NCT03659734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Following surgery, participants will receive phone calls from a trained member of the study staff to discuss various aspects of surgical recovery and medication use. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
Study NCT04263051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCPVax + Nivolumab
Description: UCPVax will be administrated at day 1 of week 1 ; 2 ; 3 ; 5 ; 6 ; 7 and then week 13 and every 2 months until months 12.~Nivolumab will be administrated at the dose of 480 mg at day 1 and then every 4 weeks until disease progression or unacceptable toxicity according to label.~At the end of COMBO phase, nivolumab will be continued every 4 weeks for maximum 24 months from the first administration, until disease progression or unacceptable toxicity according to standard of care.
Study NCT04263051 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: standard chemotherapy
Description: Second line chemotherapy at the choice of the investigator
Study NCT01135043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education by brochure
Description: educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
Study NCT01135043 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure
Study NCT03367299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Blinatumomab
Description: Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.
Study NCT03830762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanamem
Description: Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.
Study NCT03830762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.
Study NCT00217737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00217737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT00217737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT00217737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00217737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00217737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT00217737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT00217737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV
Study NCT00217737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT02772536 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visual Stimulus Condition Set
Description: In this single arm study, all participants are subject to a set of three visual stimulus conditions.~Low ambient light for 10 mins: Self selected tinted light (20 Mins); White light (20 mins).~VAS/CGI scores for each stimulus condition in the above set are reported at five minute intervals.
Study NCT01669395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early homebased rehabilitation after hospital admission
Description: Training begins 3-5 days after discharge from hospital, performed by an occupational therapist and a physiotherapist from Gentofte Hospital in the first two weeks. From week three to six the training will be carried out by an occupational therapist and a physiotherapist from the local municipality (Gentofte municipality and Lyngby Taarbæk municipality). Training will take place at home twice a week for 6 weeks, each session lasting 45 minutes. The intervention is individualized and focuses on functional physical and compensatory training to help the patient to manage everyday life at home. A training program will be provided and the patient will be instructed to do the exercises every day
Study NCT01669395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
Study NCT04287881 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Methylenetetrahydrofolate reductase (MTHFR) deficiency
Description: To investigate the incidence of MTHFR deficiency in patients with adult-onset epileptic seizures and diagnosed ischemic stroke
Study NCT02594462 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: etonogestrel-releasing implant contraceptive
Description: The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.
Study NCT03317613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qutenza
Description: Patients suffering from neuropathic pain will receive patch of capsaicin (qutenza) on the painful zones. Three months after the first application, patients will be allowed to receive another patch if necessary. They will be able to receive one every three months. They will be followed in the study during one year after the first patch application.
Study NCT00001337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH
Description: Combination chemotherapy given with Rituximab (EPOCH-R) IV every 3 weeks for 6 cycles.
Study NCT00001337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab given on Day 1 of combination chemotherapy (EPOCH-R) every 3 weeks for 6 cycles.
Study NCT00156949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa DT
Description: Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
Study NCT04236765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TB infection-screening benefiting group
Description: The children who participate in the study will be recruited during a programmed visit to a traveler health clinic or a primary care center. During the first visit the parents or legal guardian will be interviewed, a questionnaire will be completed with sociodemographic, epidemiologic and clinical data and a tuberculin skin test (TST) will be performed and read at 48-72 hours. At 8-12 weeks after returning from the travel abroad the child will have a new visit. A new interview will be carried out with the parents or legal guardian and a questionnaire will be completed with epidemiological and clinical data. The child will undergo a new TST and QFT-Plus test.
Study NCT02328781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent
Study NCT02879279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo, Pablo, Diego and Motore.
Description: In the robotic rehabilitation group, patients will be treated with the following systems: Amadeo, Pablo and Diego (Tyromotion GmbH, Austria), and Motore (Humanware, Italy). A ratio of one therapist to every 3 or 4 patients will be used, depending on the patient's severity. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
Study NCT02879279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: In the conventional rehabilitation group, patients will undergo a conventional treatment with a ratio of one therapist to one patient. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
Study NCT00368277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning
Study NCT00368277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning
Study NCT00368277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning
Study NCT00368277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning
Study NCT00368277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning
Study NCT00368277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning
Study NCT02241603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Obese Veterans will undergo dietary education for weight loss or weight maintenance
Study NCT01484821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ARFI
Description: Muscle sonoelastography using ARFI(Acoustic Radiation Force Impulse) imaging
Study NCT01484821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARFI
Description: Muscle sonoelastography using ARFI(Acoustic Radiation Force Impulse) imaging
Study NCT01852513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QNASL
Study NCT01852513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Study NCT00748163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Study NCT00748163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study NCT04008888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Allogeneic Stem Cell Transplant: Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients.
Study NCT04008888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2
Description: Autologous hematopoietic stem cell transplantation :Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day followed collecting CD34+ peripheral blood stem cells . Day 0 Infusion of autologous stem cells. Patients during 3-6 months after the 1st SCT will undergo a 2nd SCT. Patients who had not enough PBSC will undergo a 1st SCT.
Study NCT04008888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Given IV
Description: conditioning regimen: autologous ARM: Day -2 Melphalan 200 mg/m\^2/day IV over 30 minutes. allogeneic ARM: Day -4, Day -3 Melphalan 70 mg/m\^2/day IV over 30 minutes
Study NCT04008888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Injection
Description: conditioning regimen:Days -6,-5,-4,-3 Fludarabine 30 mg/m\^2/day IV
Study NCT04008888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI and dexamethasone as maintenance therapy
Description: Bortezomib and dexamethasone(VD),Ixazomib and dexamethasone(ID)
Study NCT04008888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI+IMids+Dexamethasone as Consolidated Chemotherapy
Description: Oral lenalidomide at the starting dose of 25mg on days 1-21 every 28 days or days 1-14 every 21 days. Dexamethasone at 20mg twice weekly on days 1,2,4,5,8,9,11\&12 of each 21-day.
Study NCT03853395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tests for drug levels and anti-drug antibodies
Description: Measurement of drug levels and anti-drug antibodies will be undertaken using commercially available enzyme-linked immunosorbent assays (ELISAs) and/or radioimmunoassays
Study NCT03853395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests for drug levels and anti-drug antibodies
Description: Measurement of drug levels and anti-drug antibodies will be undertaken using commercially available enzyme-linked immunosorbent assays (ELISAs) and/or radioimmunoassays
Study NCT04221945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT04221945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for pembrolizumab
Description: IV infusion
Study NCT04221945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT04221945 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
Study NCT04221945 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
Study NCT01660607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ Hematopoietic Progenitor Cells (HSPC)
Description: Purified CD34+ hematopoietic progenitor cells used in transplantation.
Study NCT01660607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regulatory T-Cells (Treg)
Description: Highly purified CD4+CD25+CD127-FoxP3+ regulatory T cells to reduce graft-versus-host disease.
Study NCT01660607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conventional T-Cells (Tcon)
Description: Conventional CD3+ T cells used for immune reconstitution and graft enhancement.
Study NCT01660607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myeloablative Conditioning Regimen
Description: Chemotherapy or total body irradiation used before hematopoietic cell transplantation.
Study NCT01368523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Study NCT04531332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion Linezolid
Description: Linezolid 600 mg intravenous Loading dose followed by 1200 mg/ day by Continuous infusion ( 50 mg /hr )
Study NCT04531332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intermittent dosing linezolid
Description: Linezolid 600 mg intravenous twice daily
Study NCT03300440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics and vitamin B7
Description: Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form (7,5 x 109 CFU) Bacteria strains: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactobacillus acidophilus W22 Lactobacillus casei W56 Lactobacillus paracasei W20 Lactobacillus plantarum W62 Lactobacillus salivarius W24 Lactococcus lactis W19 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
Study NCT03300440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and vitamin B7
Description: Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
Study NCT01463800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured exercise training
Description: 12 weeks low level ambulatory structured exercise training
Study NCT02996890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-ZIKA
Description: MV-Zika vaccine
Study NCT02996890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: physiological saline
Study NCT02996890 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: physiological saline
Study NCT03665181 — intervention group
Intervention type: OTHER
Intervention: use or non-use of dose modulator and bismuth mask
Description: For each child for who the eligibility criteria are met, the CT exam is perfomed with or without dose modulator associated to with or without bismuth mask
Study NCT02106065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Skill-Building Rehabilitation (ESBR)
Description: ESBR intervention consists of four, 90-minute sessions over a 4-6 week period. These four sessions are supplemented with booster sessions at 3 and 9 months post-intervention. Each group session (10 or fewer participants) is attended either in-clinic or via video telehealth technology within the VAPAHCS.
Study NCT02106065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental Education Materials
Description: Participants randomized to the Usual Care (UC) group will receive supplemental educational materials related to aging and dementia.
Study NCT03696381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real tRNS
Description: The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. During the first 20 minutes of each cognitive training session, patients will receive bi-frontal and bi-parietal tRNS. It has a start and end ramp of two seconds in each case to avoid the slight unpleasant sensation that occurs in the first moments of the introduction of direct current DC.
Study NCT03696381 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tRNS
Description: The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. We will apply a sham tRNS for the first 20 minutes of each cognitive training session. The subjects will receive sham tRNS and will perform the same type of cognitive training as the rest of patients and will receive the same type of adverse reaction questionnaire. Subjects receiving simulated stimulation will receive the same type of ramps at the beginning and end of the session to ensure triple-blind maintenance .
Study NCT00836836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet
Description: Modified Atkins Diet administration~1. Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided.
Study NCT01801670 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: Two 6 mm skin punch biopsies (one from pruritic skin and from involved non pruritic skin).
Study NCT01801670 — intervention group
Intervention type: PROCEDURE
Intervention: Blood
Description: Peripheral blood (10 mls) to be drawn and used for cytokine analysis.